2025
In‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial
Nouhravesh N, Cyr D, Hernandez A, Morrow D, Velazquez E, Ward J, Sarwat S, Sharma K, Williamson K, Starling R, Lepage S, Zieroth S, Solomon S, Mentz R. In‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial. Journal Of The American Heart Association 2025, 14: e037899. PMID: 39968788, PMCID: PMC12132675, DOI: 10.1161/jaha.124.037899.Peer-Reviewed Original ResearchOut-of-hospitalWorsening renal functionSafety end pointNT-proBNP changesEjection fractionIn-hospitalNT-proBNPHeart failureRenal functionSymptomatic hypotensionTime-averaged proportional changeEnd pointsWorsening heart failure eventEffects of Sac/ValSacubitril/valsartan (sac/valWorsening HF eventsHeart failure eventsStatistically significant differenceWorsening HFDouble-blindHF hospitalizationSac/ValCardiovascular deathWeek 4HF events
2024
Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial
Ranade M, Foster M, Brady P, Sokol S, Butty S, Klein A, Maholic R, Safar A, Patel T, Zlotnick D, Gans D, Pollak J, Ferrera D, Stegman B, Basra S, Moriarty J, Keeling B, Investigators A. Novel Mechanical Aspiration Thrombectomy in Patients With Acute Pulmonary Embolism: Results From the Prospective APEX-AV Trial. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 4: 102463. PMID: 40061412, PMCID: PMC11887559, DOI: 10.1016/j.jscai.2024.102463.Peer-Reviewed Original ResearchAcute intermediate-risk PEMechanical aspiration thrombectomyIntermediate-risk PEPulmonary embolismAspiration thrombectomyRV/LV ratioClot burdenAdverse eventsMm HgLow rate of adverse eventsMean pulmonary artery pressureEnd pointsRate of adverse eventsAcute pulmonary embolismPulmonary artery pressureSafety end pointDevice-related deathsTreat pulmonary embolismSingle-arm studyEffectiveness end pointAccess site bleedingStatistically significant reductionCardiac injuryClinical deteriorationArterial pressureEquity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study
McEntegart M, Gonzalo N, Fendelander L, West N, Lansky A. Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102289. PMID: 39649816, PMCID: PMC11624350, DOI: 10.1016/j.jscai.2024.102289.Peer-Reviewed Original ResearchCoronary artery diseaseCalcified coronary artery diseasePercutaneous coronary interventionTarget lesion failureCoronary intravascular lithotripsyArtery diseaseFemale patientsIntravascular lithotripsySubcohort analysis of patientsPrevalence of coronary artery calcificationEnd pointsOptical coherence tomography imagesComposite of cardiac deathClinical events committeeSafety end pointAnalysis of patientsIndependent core laboratoryIncreased risk of mortalityIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionTarget lesion revascularizationCoronary artery calcificationEffectiveness end pointCAD studiesCardiology clinical trialsOutcomes With the WATCHMAN FLX in Everyday Clinical Practice From the NCDR Left Atrial Appendage Occlusion Registry
Kapadia S, Yeh R, Price M, Piccini J, Nair D, Bansal A, Hsu J, Freeman J, Christen T, Allocco D, Gibson D. Outcomes With the WATCHMAN FLX in Everyday Clinical Practice From the NCDR Left Atrial Appendage Occlusion Registry. Circulation Cardiovascular Interventions 2024, 17: e013750. PMID: 39056187, DOI: 10.1161/circinterventions.123.013750.Peer-Reviewed Original ResearchClinical practiceHospital dischargeSafety end pointIschemic strokeWatchman FLX deviceWatchman FLXEveryday clinical practiceFLX deviceAll-cause deathRegistryAdverse eventsAnalysis planRate of implant successEnd pointsImprove outcomesLow incidence of adverse eventsIncidence of adverse eventsCohort of patientsOpen cardiac surgeryPeri-device leakProcedure-related eventsDays post-procedureMajor adverse eventsDevice-related thrombusStroke
2023
Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials
Kiernan E, Hu D, Philbrook H, Ix J, Bonventre J, Coca S, Moledina D, Fried L, Shlipak M, Parikh C. Urinary Biomarkers and Kidney Injury in VA NEPHRON-D: Phenotyping Acute Kidney Injury in Clinical Trials. American Journal Of Kidney Diseases 2023, 83: 151-161. PMID: 37726051, PMCID: PMC10841767, DOI: 10.1053/j.ajkd.2023.07.012.Peer-Reviewed Original ResearchAcute kidney injuryKidney injuryClinical trialsSerum creatinineUrinary biomarkersAKI eventsVA NEPHRONCombination armUrine biomarkersDiabetic chronic kidney disease patientsChronic Kidney Disease trialChronic kidney disease patientsAldosterone system blockadeCombination therapy armKidney Disease TrialRAAS inhibitor therapySafety end pointCombination therapy groupKidney disease patientsBiomarkers of injuryAKI incidenceKidney outcomesMonotherapy armRAAS blockadeRAASi therapyPredicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months
Johnson M, Spies J, Scott K, Kato B, Mu X, Rectenwald J, White R, Lewandowski R, Khaja M, Zuckerman D, Casciani T, Gillespie D. Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months. Journal Of Vascular And Interventional Radiology 2023, 34: 517-528.e6. PMID: 36841633, DOI: 10.1016/j.jvir.2022.12.009.Peer-Reviewed Original ResearchConceptsVena cava filtersEnd pointCava filtersPrimary effectiveness end pointPrimary safety end pointInferior vena cava filterEffectiveness end pointSafety end pointVenous thromboembolic eventsProphylactic placementAnticoagulation therapyThromboembolic eventsVenous thromboembolismThrombotic occlusionNonrandomized studyPrimary safetyTomography scanLower incidenceSignificant PESite investigatorsPatientsCore laboratoryStrut perforationMonthsDVTPredicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months
Johnson M, Spies J, Scott K, Kato B, Mu X, Rectenwald J, White R, Lewandowski R, Khaja M, Zuckerman D, Casciani T, Gillespie D. Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE): Outcomes at 12 months. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2023, 11: 573-585.e6. PMID: 36872169, DOI: 10.1016/j.jvsv.2022.11.002.Peer-Reviewed Original ResearchConceptsVena cava filtersEnd pointCava filtersPrimary effectiveness end pointPrimary safety end pointInferior vena cava filterEffectiveness end pointSafety end pointVenous thromboembolic eventsProphylactic placementAnticoagulation therapyThromboembolic eventsVenous thromboembolismThrombotic occlusionNonrandomized studyPrimary safetyTomography scanLower incidenceSignificant PESite investigatorsPatientsCore laboratoryStrut perforationMonthsDVT
2022
ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor
Singer DE, Atlas SJ, Go AS, Lopes RD, Lubitz SA, McManus DD, Revkin JH, Mills D, Crosson LA, Lenane JC, Aronson RS. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. American Heart Journal 2022, 249: 76-85. PMID: 35472303, DOI: 10.1016/j.ahj.2022.04.005.Peer-Reviewed Original ResearchConceptsOral anticoagulant therapyEfficacy end pointSafety end pointUndiagnosed atrial fibrillationAtrial fibrillationEnd pointAF screeningLong-term oral anticoagulant therapyIndividuals age 70 yearsRate of strokeProportion of patientsScreen-detected casesNovel coronavirus disease 2019 (COVID-19) pandemicAge 70 yearsParoxysmal atrial fibrillationCoronavirus disease 2019 (COVID-19) pandemicPrimary care practicesTarget sample sizeDisease 2019 pandemicLong-term screeningElectronic health recordsBleeding outcomesScreening armAF burdenUsual careRandomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse eventsSex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies
Hussain Y, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100011. PMID: 39130137, PMCID: PMC11307712, DOI: 10.1016/j.jscai.2021.100011.Peer-Reviewed Original ResearchPrimary efficacy end pointPrimary safety end pointMajor adverse cardiovascular eventsAdverse cardiovascular eventsEfficacy end pointSafety end pointIntravascular lithotripsyEnd pointCardiovascular eventsMyocardial infarctionHospital major adverse cardiovascular eventsMean reference vessel diameterCoronary intravascular lithotripsySevere coronary calcificationCoronary artery calcificationReference vessel diameterPercutaneous coronary interventionPrior myocardial infarctionSex-based outcomesSex-specific outcomesSide branch involvementPatient-level analysisSmall vessel sizeAngiographic complicationsLesion predilatationEffect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism
Goldenberg N, Kittelson J, Abshire T, Bonaca M, Casella J, Dale R, Halperin J, Hamblin F, Kessler C, Manco-Johnson M, Sidonio R, Spyropoulos A, Steg P, Turpie A, Schulman S, French J, Fargo J, Crary S, Kumar R, Grace R, Trenor C, Wilson H, Hilliard L, Woods G, Patel K, Goldenberg N, Lowe E, Jaffray J, Young G, Rajpurkar M, Davila J, Mahajerin A, Cooper J, Gunawardena S, Zia A, Journeycake J, Carpenter S, Guerrera M, Diab Y, Tarango C, Gruppo R, Acharya S, Torres M, Shaffer L, Mignacca R, Haley K, Recht M, Thornburg C, Shah N, Mullen C, Mitchell D, Nakar C, Betensky M, Lawrence C, Takemoto C, Lo C, Scott-Emuakpor A, Kulkarni R, Borst A, O'Brien S, Corales-Medina F, Narang S, Kucine N, Wang M, Panigrahi A, McGowan K, Cramer S, Dandekar S, Xavier F, Knoll K, Verma A, Geddes A, Ahuja S, Hege K, Raybagkar D, Sharathkumar A, Srivath L, Khan O, Druzgal C, Bhatt M, Chan A, Brandao L, Massicotte P, van Ommen C, Male C, Monagle P, Nakano T, Mitchell W, Hiatt W, Weitz J. Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA 2022, 327: 129-137. PMID: 35015038, PMCID: PMC8753509, DOI: 10.1001/jama.2021.23182.Peer-Reviewed Original ResearchConceptsClinically relevant bleeding eventsAnticoagulant therapy groupRecurrent venous thromboembolismSymptomatic recurrent venous thromboembolismDuration of anticoagulant therapyYears of ageAnticoagulant therapyBleeding eventsVenous thromboembolismTherapy groupAdverse eventsOptimal duration of anticoagulant therapyEnd pointsEffect of anticoagulant therapyProvoked venous thromboembolismPersistent antiphospholipid antibodiesPer-protocol populationPrimary end pointSafety end pointPrimary efficacy outcomePrimary safety outcomeVenous thromboembolism riskAbsolute risk reductionKaplan-Meier estimatesRandomized clinical trials
2021
Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis
Luo M, Zhu P, Nnane I, Xiong Y, Merlini G, Comenzo R, Kastritis E, Wechalekar A, Weiss B, Tran N, Qin X, Vermeulen J, Sharma A, Sun Y, Zhou H. Population Pharmacokinetics and Exposure‐Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light‐Chain Amyloidosis. The Journal Of Clinical Pharmacology 2021, 62: 656-669. PMID: 34708423, DOI: 10.1002/jcph.1994.Peer-Reviewed Original ResearchConceptsLight chain amyloidosisSafety end pointSystemic exposureExposure-response analysesEnd pointsPopulation pharmacokineticsAmyloid light-chain amyloidosisNo dose adjustmentEfficacy end pointSystemic amyloid light-chain amyloidosisExposure-responseTreatment of light-chain amyloidosisImpact of potential covariatesLogistic regression analysisNonlinear mixed-effects modelingConcentration-time dataDexamethasone regimenDose adjustmentHematologic responseDaratumumabImmunogenicity dataPopPK analysisPopPK modelEvaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors
Long AS, Zhang AD, Meyer CE, Egilman AC, Ross JS, Wallach JD. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors. JAMA Network Open 2021, 4: e215731. PMID: 33956134, PMCID: PMC8103227, DOI: 10.1001/jamanetworkopen.2021.5731.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsSafety end pointEnd pointClinical trialsDrug pairsPrimary end point resultsEnd point resultsImproved efficacyEfficacy end pointCochrane Central RegistrySeparate end pointsSingle-enantiomer drugsSingle enantiomer formulationPrimary efficacySecondary efficacyControlled TrialsOvid EmbaseOvid MEDLINESuperior efficacyDrug AdministrationCentral RegistrySystematic reviewMore efficacyTrialsRacemic drugs
2020
Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Luo M, Usmani S, Mateos M, Nahi H, Chari A, San‐Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun Y, Parasrampuria D. Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. The Journal Of Clinical Pharmacology 2020, 61: 614-627. PMID: 33145788, PMCID: PMC8048619, DOI: 10.1002/jcph.1771.Peer-Reviewed Original ResearchConceptsSubcutaneous formulation of daratumumabIncidence of neutropeniaIntravenous daratumumabMonotherapy studiesCombination therapySubcutaneous daratumumabPK samplingStandard-of-care regimensPeak-to-trough fluctuationHigher trough concentrationsCombination therapy studiesSafety end pointMultiple myeloma patientsPopulation pharmacokinetic analysisCycle 1Flat doseExposure-response analysesMyeloma patientsDaratumumabTrough concentrationsSubcutaneous formulationPharmacokinetic analysisTreatment periodTherapy studiesNeutropeniaPhenobarbital Monotherapy for the Management of Alcohol Withdrawal Syndrome in Surgical-Trauma Patients
Ammar MA, Ammar AA, Rosen J, Kassab HS, Becher RD. Phenobarbital Monotherapy for the Management of Alcohol Withdrawal Syndrome in Surgical-Trauma Patients. Annals Of Pharmacotherapy 2020, 55: 294-302. PMID: 32830517, DOI: 10.1177/1060028020949137.Peer-Reviewed Original ResearchConceptsManagement of AWSAlcohol withdrawal syndromePhenobarbital monotherapyRespiratory depressionWithdrawal syndromeDevelopment of AWSSurgical trauma intensive care unitPatient experienced hypotensionSurgical trauma patientsInvasive mechanical ventilationSafety end pointFirst-line therapyMajority of patientsManagement of patientsIntensive care unitExperienced hypotensionTaper regimenSignificant hypotensionAdjunct therapyIll patientsLoading doseCare unitMechanical ventilationPatient populationSurgical traumaPulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis
Katsanos A, Alexandrov A, Mandava P, Köhrmann M, Soinne L, Barreto A, Sharma V, Mikulik R, Muir K, Rothlisberger T, Grotta J, Levi C, Molina C, Saqqur M, Palaiodimou L, Psaltopoulou T, Vosko M, Moreira T, Fiebach J, Rubiera M, Sandset E, de Havenon A, Kent T, Alexandrov A, Schellinger P, Tsivgoulis G, Investigators F. Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis. European Journal Of Neurology 2020, 27: 2453-2462. PMID: 32697894, DOI: 10.1111/ene.14447.Peer-Reviewed Original ResearchConceptsPatients treated with intravenous thrombolysisAcute ischaemic strokeIndependent functional outcomePulse pressure variabilityIntravenous thrombolysisIntracranial bleedingAssociated with adverse short-termFunctional outcomesBlood pressureStroke patients treated with intravenous thrombolysisTissue plasminogen activator bolusSystemic tissue plasminogen activatorAssociated with unfavorable outcomesAssociated with worse neurological outcomeSymptomatic intracranial bleedingLong-term functional outcomeSafety end pointPulse pressureAcute ischaemic stroke patientsAdverse short-termLysis of thrombiPressure variabilityTissue plasminogen activatorCombined Lysis of ThrombusIntravenous thrombolysis administrationActive Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures
Resnic F, Majithia A, Dhruva S, Ssemaganda H, Robbins S, Marinac-Dabic D, Hewitt K, Ohno-Machado L, Reynolds M, Matheny M. Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006105. PMID: 32283971, PMCID: PMC7360169, DOI: 10.1161/circoutcomes.119.006105.Peer-Reviewed Original ResearchConceptsICD RegistryLead failureActive surveillanceNational Cardiovascular Data Registry ICD RegistryImplantable Cardioverter-Defibrillator RegistryPrimary safety end pointPropensity-matched survival analysisRate of freedomSafety end pointLead failure rateLong-term safetySignificant patient harmDefibrillator lead failureEarly lead failureMonitoring of safetyComparator patientsContemporary ICDLead survivalMeaningful differencesOutcome ascertainmentFailure rateNew ICDPatient harmPatientsSurvival analysis
2019
Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation
Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, Ziese E, Romano MA, Bolling SF, Group M. Outcomes of Guideline-Directed Concomitant Annuloplasty for Functional Tricuspid Regurgitation. The Annals Of Thoracic Surgery 2019, 109: 1227-1232. PMID: 31479635, PMCID: PMC7048637, DOI: 10.1016/j.athoracsur.2019.07.035.Peer-Reviewed Original ResearchConceptsConcomitant tricuspid valve repairTricuspid valve repairRecurrent tricuspid regurgitationTricuspid regurgitationFunctional tricuspid regurgitationValve repairConcomitant coronary artery bypassLeft-sided valve surgeryPreoperative atrial fibrillationWorse tricuspid regurgitationCoronary artery bypassRight ventricular remodelingSafety end pointRight ventricular performanceComplex aortic surgeryPreoperative tricuspid regurgitationRight ventricular dimensionsFear of complicationsFunctional mitral regurgitationActive endocarditisAortic surgeryArtery bypassValve surgeryConsecutive patientsPacemaker placementInhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients
Enomoto TM, Treggiari MM, Yanez ND, Merkel MJ. Inhaled Iloprost Versus Epoprostenol in Heart Transplant Recipients. Respiratory Care 2019, 64: 743-751. PMID: 30967439, DOI: 10.4187/respcare.06426.Peer-Reviewed Original ResearchConceptsAcute right ventricular dysfunctionHeart transplant recipientsRight ventricular dysfunctionMechanical ventilationEnd pointHeart transplantationHospital stayTransplant recipientsVentricular dysfunctionHemodynamic valuesMedian numberAcute pulmonary hypertensionLength of ICUOrthotopic heart transplantationPrimary end pointSafety end pointSecondary end pointsImmediate postoperative periodPrimary vasodilatorVasoactive medicationsVasodilatory therapyPostoperative bleedingPulmonary hypertensionPostoperative periodConsecutive patients
2018
Radiofrequency versus Cryoballoon Ablation of Atrial Fibrillation: An Evaluation Using ECG, Holter Monitoring, and Implantable Loop Recorders to Monitor Absolute and Clinical Effectiveness
Davtyan K, Shatakhtsyan V, Poghosyan H, Deev A, Tarasov A, Kharlap M, Serdyuk S, Simonyan G, Boytcov S. Radiofrequency versus Cryoballoon Ablation of Atrial Fibrillation: An Evaluation Using ECG, Holter Monitoring, and Implantable Loop Recorders to Monitor Absolute and Clinical Effectiveness. BioMed Research International 2018, 2018: 3629384. PMID: 29721503, PMCID: PMC5867681, DOI: 10.1155/2018/3629384.Peer-Reviewed Original ResearchConceptsEfficacy end pointCryoballoon groupCryoballoon ablationRadiofrequency currentAtrial fibrillationEnd pointsClinical effectsBlanking periodSecondary efficacy end pointsAblation of atrial fibrillationNonvalvular paroxysmal AFPostablation blanking periodRate of adverse eventsFollow-up durationSafety end pointBaseline patient characteristicsTreatment of patientsLong-term efficacyLong-term outcomesImplantable loop recorderCryoballoon ablation of atrial fibrillationConsecutive patientsParoxysmal AFFollow-up methodsAsymptomatic episodes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply